랜턴 파마 (LTRN) 주가

랜턴 파마(LTRN)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $2.65 (+0.76%), 시가총액 $0.04B, 52주 범위 $1.12 ~ $5.32.

Lantern Pharma Inc. focuses on the discovery and development of oncology drug in India. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1a clinical trial for the treatment of advanced or metastatic solid tumors, or unresectable or recurrent GBM, solid tumor, such as pancreatic, breast, bladder, and lung cancers, as well as glioblastoma and other central nervous system (CNS) cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma. The company also develop

핵심 지표

• 현재가: $2.65 (+0.76%)
• 시가총액: $0.04B
• 52주 최저~최고: $1.12 ~ $5.32
• 섹터: Healthcare
• 산업: Biotechnology
• 거래소: NASDAQ

랜턴 파마의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackQuant에서 실시간으로 확인할 수 있습니다.

랜턴 파마 재무 요약

애널리스트 전망

• 투자의견 컨센서스: 5

핵심 재무비율 · 수익성 · 성장성

• PBR (주가순자산비율): 11.70
• 순이익률: 0.00%
• 영업이익률: 0.00%

자주 묻는 질문